Compare RGLD & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | RPRX |
|---|---|---|
| Founded | 1981 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 16.2B |
| IPO Year | N/A | 2020 |
| Metric | RGLD | RPRX |
|---|---|---|
| Price | $209.32 | $38.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $213.38 | $46.00 |
| AVG Volume (30 Days) | 726.8K | ★ 4.0M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | 0.86% | ★ 2.30% |
| EPS Growth | ★ 66.97 | N/A |
| EPS | ★ 7.28 | 1.75 |
| Revenue | $849,255,000.00 | ★ $2,349,844,000.00 |
| Revenue This Year | $25.73 | $37.13 |
| Revenue Next Year | $64.70 | $1.48 |
| P/E Ratio | $28.77 | ★ $21.84 |
| Revenue Growth | ★ 28.17 | 3.70 |
| 52 Week Low | $130.67 | $24.05 |
| 52 Week High | $209.43 | $41.24 |
| Indicator | RGLD | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 46.84 |
| Support Level | $198.14 | $39.24 |
| Resistance Level | $207.66 | $39.88 |
| Average True Range (ATR) | 5.69 | 0.89 |
| MACD | 1.21 | -0.24 |
| Stochastic Oscillator | 98.87 | 34.95 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.